Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.
|Articles|January 3, 2017
CPhI 2016 Excellence in Pharma: Packaging Award Winner Interview
Pylote SA discusses its Pyclear Protection packaging innovation.
Advertisement
The CPhI Pharma Awards 2016, Excellence in Pharma: Packaging was awarded to Pyclear Protection, an innovative packaging material from Pylote SA. Pharmaceutical Technology spoke with Loïc Marchin, CEO of Pylote, about the technology.
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Rare Pediatric PRVs: Manufacturing Strategies for Expedited Approval, Part 1
2
Manufacturing Intelligence: What FDA's Real-World Use Case Database Means for CMC
3
FDA Rare Disease Framework Puts CMC Review in Scope
4
PharmTech AI Pulse Check: AI Watermark Vulnerability
5